Igor Bilinsky - Jan 17, 2023 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Operating Officer
Signature
/s/ Igor Bilinsky
Stock symbol
IOVA
Transactions as of
Jan 17, 2023
Transactions value $
-$30,035
Form type
4
Date filed
1/19/2023, 03:52 PM
Previous filing
Jan 5, 2023
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOVA Common Stock Options Exercise $0 +11.2K +63.19% $0.00 29K Jan 17, 2023 Direct F1
transaction IOVA Common Stock Tax liability -$30K -4.67K -16.08% $6.43 24.4K Jan 17, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Restricted Stock Units Options Exercise $0 -11.2K -33.33% $0.00 22.5K Jan 17, 2023 Common stock 11.2K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the restricted stock units ("RSUs") issued to the Reporting Person on January 14, 2022, vested on January 14, 2023. The vested RSUs were settled on January 17, 2023.
F2 Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
F3 Represents common stock remaining after deducting the common stock withheld for taxes.
F4 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F5 The remaining RSUs will vest in eight equal quarterly installments over the next two years.